Supplemental Table 3. Real-world time on treatment among patients with R/M HNSCC who received 1L platinum monotherapy

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  |  | Second-line therapy | | |
|  |  | All patients  (N=228) | I-O monotherapy  (N=138) | Non-I-O therapy  (N=83) |
| Patient follow-up, months A |  | 6.8 (0.0 – 27.3) | 6.3 (0.0 – 27.3) | 8.2 (0.0 – 26.9) |
| Time on treatment, months B |  | 2.4 (1.9 – 3.0) | 3.5 (2.3 – 5.6) | 1.4 (1.2 – 1.9) |
| On-treatment rate C |  |  |  |  |
| 6 months |  | 27.1% (21.1 - 33.3) | 39.9% (31.3 – 48.3) | 5.17% (1.68 – 11.7) |
| 12 months |  | 16.4% (11.3 – 22.4) | 25.7% (17.7 – 34.4) | 1.29% (0.11 – 6.21) |
| 18 months |  | 9.38% (4.65 - 16.1) | 16.1% (8.16 – 26.5) | - |

I-O, immuno-oncology

A Patient follow-up was defined as time from second-line initiation to date of death or data cutoff, whichever occurred first. Values are presented as median (95% CI) months.

B Time on second-line therapy. Values are presented as median (95% CI). Based on the Kaplan-Meier time-to-event model.

C Values are presented as percent (95% CI). Based on the Kaplan-Meier time-to-event model.